Diagonal Bio AB (publ) provides a point-of-care testing system for genetic markers that detects viruses, bacteria and fungi in Sweden. The company offers LAMPlify, a system used to identify the presence of specific genetic markers, such as fungi, viruses, or bacteria. It is also involved in the development of PANVIRAL, a universal in vitro diagnostic system, that offers the potential for rapid and accurate point-of-care diagnoses in various settings, such as doctor’s office, surgery, mobile clinics, hospital bedsides, and workplaces and airports. The company was incorporated in 2020 and is based in Lund, Sweden.
Metrics to compare | DIABIO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipDIABIOPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.9x | −19.3x | −0.6x | |
PEG Ratio | −0.02 | 0.00 | 0.00 | |
Price/Book | 0.3x | 8.3x | 2.6x | |
Price / LTM Sales | 5.9x | 18.4x | 3.3x | |
Upside (Analyst Target) | - | 63.5% | 43.4% | |
Fair Value Upside | Unlock | 8.8% | 6.3% | Unlock |